Skip to main content
. Author manuscript; available in PMC: 2008 Jun 2.
Published in final edited form as: J Immunol. 2008 Mar 1;180(5):2981–2988. doi: 10.4049/jimmunol.180.5.2981

Figure 3. Anti-CD40 and IL-2 immunotherapy results in an increased surface expression of B7-H1 on all hematopoietic cells.

Figure 3

Mice were treated with anti-CD40 and IL-2 according to the standard regimen listed in the Materials and Methods section. 11 days after treatment initiation, spleen were harvested and analyzed by flow cytometry for surface B7-H1 expression. (A) B7-H1 (PDL-1) expression was determined by median fluorescence intensity analysis and is significantly (P < 0.0001 by unpaired student t test) higher on splenocytes from animals which received anti-CD40 and IL-2. (B) Representative histograms show a similar pattern in both C57BL/6 mice as well as BALB/c mice; unlabeled control (gray line) and labeling with anti-B7-H1 antibody (clone MIH5) on CD45+ splenocytes from control treated animals (dashed black line) and animals treated with anti-CD40 and IL-2 (solid black line). (C) A comparison of the MFI of B7-H1 on CD45+ cells in control treated animals versus anti-CD40 and IL-2 treated animals, a one way ANOVA was used for statistical analysis. Each experiment was made up of three mice per group. The data shown in B and C were collected on two different flow cytometers (Beckman Coulter XL and FacScan, respectively) and the Y axes are representative of the MFI as reported by the two instruments. Experiments shown in A were completed at least three times with similar results, data in B and C was completed one time (n=3 for each).